retatrutide biolongevity labs GLP-3 BL-ENDO-250401-003 Retatrutide – 24mg – Prime
Description
, Parthsarathy, V
A large cohort study found the gastroparesis and pancreatitis risk figures cited above among patients using GLP-1 agonists specifically for weight loss, not diabetes
Drucker et al
The mechanism appears to involve altered dopamine signaling in reward pathways
About 50% of patients discontinue GLP-1 therapy within one year, and roughly 70% stop within two years usually because of cost, side effects, or a belief that they can maintain results without the medication
Fair Use Statement The information in this article may be shared for noncommercial purposes only
